alexa Use Of BRAF V600E Mutation In The Prognostication Of Thyroid Cancer
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference on Translational Medicine
November 03-05, 2014 Las Vegas, USA

Mingzhao Xing
Keynote: Transl Med
DOI: 10.4172/2161-1025.S1.011
Abstract
Thyroid cancer is a common endocrine malignancy with a rapidly rising incidence in many countries in recent years. Most cases of thyroid cancer have a good prognosis, but some seem to be bound to poor outcomes with increased disease recurrence, treatment refractoriness, and mortality. Conventional approach to risk stratification of thyroid cancer is solely based on clinicopathological criteria, which has proven tobe often ineffective. An area that is revolutionizing the risk stratification and hence management of thyroid cancer is the clinical translational research onprognostic molecular markers in thyroid cancer, as best exemplified by BRAFV600E mutation. Numerous studies have demonstrated a strong association of BRAF V600E mutation with poor clinicopathological characteristics of PTC, such as lymph node metastasis, extrathyroidal invasion, advanced tumor stages, tumor recurrence, and patient mortality, establishing a remarkable prognostic value of this molecular marker. BRAF mutation can be detected on thyroid fine needle aspiration biopsy specimens, so this prognostic marker can be used even preoperatively to assist risk stratification and surgical and medical managements at an early stage of the treatment of thyroid cancer. The use of the recently discovered TERT promoter mutations in combination with BRAF mutation makes even more effective this molecular marker-based risk stratification and hence tailored management of thyroid cancer. Our group has played a leading role in the last 10 years in the discovery and characterization of these prominent molecular markers in thyroid cancer. This presentation will provide a comprehensive discussion on this exciting clinical translational research area of thyroid cancer medicine.
Biography
Mingzhao Xing, MD, PhD, is Professor of Medicine, Oncology and Pathology, Co-Director of the Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine.He subsequently completed his medical residency at the Greater Baltimore Medical Center and clinical fellowship in endocrinology and metabolism at the Johns Hopkins Hospital before joining the Johns Hopkins endocrine faculty.Dually certified in Internal Medicine and Endocrinology, he practices clinical endocrinology as a subspecialty consultant and teaching attending at the Johns Hopkins Hospital while leading a research laboratory there focused on thyroid studies as a physician scientist.Supported by the American Cancer Society and NIH R0-1 grants, his laboratory has been studying molecular, genetic, and epigenetic mechanisms of thyroid cancer and their clinical translation.He has published extensively in prestigious journals including Journal of Clinical Endocrinology and Metabolism, Cancer Research, Clinical Cancer Research, Journal of Biological Chemistry, Journal of Clinical Investigation, JNCI, Journal of ClinicalOncology, JAMA, The Lancet, and Nature Reviews Cancer. He is co-holder of the USA patent on the initial discovery and clinical characterization of the BRAF V600E mutation in thyroid cancer.He received various awards, such as the Maryland Innovator Award, American Cancer Society?s RSG Award and many more.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords